We appreciate the opportunity to respond to Maud Toulmonde and Antoine Italiano's letter. SARC028 was a phase 2 study evaluating the safety and activity of PD-1 inhibition in advanced bone and soft tissue sarcomas and emphasised collection of biospecimens to explore immune-related biomarkers.¹ We used objective response as our primary endpoint because this was a signal-finding study. We limited the soft tissue sarcoma cohort to ten patients in each of four common soft tissue sarcoma subtypes to obtain pilot data.

中文翻译：

---

肉瘤中PD-1抑制仍需调查–作者的回复

我们感谢有机会回应Maud Toulmonde和Antoine Italiano的来信。SARC028是一项2期研究，评估晚期骨和软组织肉瘤中PD-1抑制的安全性和活性，并着重收集生物标本以探索免疫相关的生物标志物。¹我们使用客观反应作为主要终点，因为这是一项信号发现研究。我们将四种常见的软组织肉瘤亚型中的软组织肉瘤队列限制为十名患者，以获取试验数据。